Mike is an actual ADSTILADRIN patient.

Clinical Study Results

ADSTILADRIN (nadofaragene firadenovec-vncg) was studied in 98 people with high-risk non–muscle-invasive bladder cancer (NMIBC) whose cancer did not respond to Bacillus Calmette-Guérin (BCG).

ADSTILADRIN was shown to be effective and have mostly mild side effects.

Gear turning icon

STIL EFFECTIVE out to 5 years

At 3 months
51%

More than half of the people who took ADSTILADRIN had a complete response (with no signs of high-grade bladder cancer) after just 1 dose (n=50).

From 1 Year out to 5 Years

Of the people treated with ADSTILADRIN who had a complete response after just 1 dose:

Select a year below to see the data

  • 1 year
  • 2 years
  • 3 years
  • 5 years

At 1 YEAR

46%

Nearly half had no signs of high-grade bladder cancer (n=25)

73%

were estimated to keep their bladder

At 2 YEARS

36%

More than 1 in 3 people had no signs of high-grade bladder cancer (n=20)

63%

were estimated to keep their bladder

At 3 YEARS

25%

1 in 4 people had no signs of high-grade bladder cancer (n=14)

54%

were estimated to keep their bladder

OUT TO 5 YEARS

Some people still had complete responses (n=6)

nearly 1/2

Nearly half
were estimated to
keep their bladder

The longest follow-up of a clinical study for an intravesical BCG-unresponsive high-risk NMIBC treatment

96%

(n=103/107)

OUT TO 5 YEARS
Of the people who received at least 1 dose of ADSTILADRIN, most did not progress to muscle-invasive bladder cancer, even if their cancer didn’t go away completely (based on results from a TURBT)

Safety shield icon

STIL HAS A MANAGEABLE SAFETY PROFILE out to 5 years

AT 1 YEAR

Most side effects (75%) were mild

and went away after a median
of JUST 2 DAYS.*

  • 11% of people had serious side effects

Only 3 out of 98 people had to stop treatment

due to side effects.

No deaths occurred

due to treatment-related side effects.

  • 34% of people interrupted treatment due to side effects but then continued treatment

OUT TO 5 YEARS

0

new side effects were reported

0

deaths due to treatment-related side effects

Bladder icon

ADSTILADRIN causes your immune system to fight NMIBC

It stops cancer cell growth and helps kill cancer cells in the bladder. It does not spread throughout your body. This may reduce side effects

Important Safety Information

INDICATION

ADSTILADRIN is a treatment for adults who have all the following:

  • High-risk non–muscle-invasive bladder cancer (NMIBC)
  • Cancer that is not responding to Bacillus Calmette-Guérin (BCG) therapy
  • Carcinoma in situ (CIS) with or without other high-grade tumors

IMPORTANT SAFETY INFORMATION

Who should not receive ADSTILADRIN?
Do not receive ADSTILADRIN if you have a sensitivity to interferon alfa or any of its components.

What is the most important information I should know about ADSTILADRIN?
Individuals who are immunosuppressed or immune-deficient should not prepare, administer, receive or come into contact with ADSTILADRIN.

What should I tell my healthcare provider?
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of ADSTILADRIN?
The most common side effects of ADSTILADRIN include:
Urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in your urine.

These are not all the possible side effects of ADSTILADRIN. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.

What other information should I know about using ADSTILADRIN?
For 2 days following treatment, voided urine should be disinfected for 15 minutes with an equal volume of bleach before flushing.

For more important information, call 1-888-337-74641-888-337-7464.

Please see full Prescribing Information.

You are now leaving the ADSTILADRIN website.